企業プロフィール
Moderna, Inc. 株価・ニュース・カタリスト
- ティッカー:
- MRNA
- 取引所:
- NASDAQ
- セクター:
- Nucleic Acid Drugs
- 所在地:
- United States
株価パフォーマンス
64.46 USD (+1.80%)
終値
最終更新: 2026年8月17日
18.1B USD
時価総額
株価変動の要因
As of Aug 17, 2026, MRNA closed up 1.80% at $64.46. No new same-company headline was identified in the current news window.
企業概要
事業概要
Moderna is a biotechnology company built around messenger RNA, with major programs spanning infectious disease, oncology, rare disease, and immunology. The company’s identity is defined by its platform and the market’s ongoing view of whether mRNA can keep producing high-value medicines.
所在地とセクター分類
Headquartered in the United States and listed on NASDAQ, Moderna is a platform biotech with a global commercial reach. It sits in the innovation-heavy part of biotechnology rather than mature pharma.
ビジネスモデルの特徴
Moderna combines platform-driven R&D with product commercialization, manufacturing scale, and broad pipeline optionality. Investors focus on vaccine demand, pipeline readouts, launch execution, and whether the platform can deliver durable post-pandemic growth.
バイオ業界での位置付け
Moderna sits near the center of modern platform biotech because it combines scientific novelty with real commercial visibility. The stock is highly sensitive to pipeline updates, regulatory milestones, and platform confidence.
今後のカタリスト
- Moderna’s key catalysts are the flu/COVID combo vaccine program, CMV vaccine data, and the Merck-partnered cancer-vaccine program. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
最近のニュース
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。